MedImmune Ventures, Inc. is a venture capital firm that operates as a subsidiary of AstraZeneca, focusing on investments in biotechnology companies at various stages, from seed to late-stage financing. The firm targets both public and private enterprises engaged in developing small and large molecule therapeutics, vaccines, medical devices, diagnostics, and healthcare technologies. Its investment scope encompasses a range of therapeutic areas, including cardiology, gastroenterology, neuroscience, oncology, and infectious diseases, among others. MedImmune Ventures aims to support the discovery, development, and commercialization of innovative pharmaceutical products globally. Established in 2002, the firm is headquartered in Gaithersburg, Maryland, with an additional office in Mountain View, California, and typically invests around $7 million in its portfolio companies.
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.
G1 Therapeutics
Series C in 2016
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.
G1 Therapeutics
Series B in 2015
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.
MdBio Foundation
Grant in 2014
MdBio Foundation, Inc. has been providing innovative and effective bioscience education for middle and high school students since 1997. The non-profit, (501 c 3) organization is dedicated to providing bioscience awareness, education, and workforce development in the state of Maryland and beyond. The Foundation accomplishes this through a diverse set of programs, including their flagship program, MdBioLab, summer programs, and their leading-edge game-based learning platform, MdBioSphere. MdBio Foundation leverages its established, trusted relationships with private industry and school systems to create authentic, STEM-based career experiences on their mobile laboratory, MdBioLab, and through their youth camp, the Young Science Explorers Program (YSEP). These experiences provide a unique opportunity for students to observe first hand the types of careers they could pursue in STEM-related fields. Students and teachers who participate in MdBioLab and YSEP have increased access to information about bioscience industry products, research, and related careers through problem-based laboratory experiences that are aligned with local, state and, national curriculum standards. Commitment to Excellence: Since its inception, The MdBio Foundation has contributed more than $3.5M of their resources to these programs and will continue to invest more than $500K each year. The Foundation’s staff consists of talented and experienced educators and scientists who share a common goal of improving science education and creating a more accessible, educational experience.
Definiens
Acquisition in 2014
Definiens is a company that specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. Its software offers detailed insights from whole tissue slides, cell-based assays, and full-body scans, enabling users to correlate this information with data from various sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating new knowledge, thereby enhancing decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, Definiens aims to advance research fields, contribute to the development of personalized medicine, and improve patient quality of life. The company also maintains offices across the United States.
VentiRx Pharmaceuticals
Series B in 2014
VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company based in Seattle, Washington, focused on developing and commercializing immunotherapies targeting Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Founded in 2006, the company’s lead investigational drug, Motolimod, works by mobilizing the patient's immune system to fight cancer through the activation of myeloid dendritic cells, monocytes, and natural killer cells. VentiRx's product pipeline includes VTX-2337, a TLR8 agonist aimed at enhancing immune responses against solid tumors and specific cancers such as ovarian and breast cancer, as well as VTX-1463, designed to address allergies. The company is also exploring TLR8 antagonists for autoimmune diseases and compounds intended as vaccine adjuvants. VentiRx Pharmaceuticals operates as a subsidiary of Celgene Corporation and has additional operations in San Diego.
Allozyne
Acquisition in 2014
Allozyne, Inc. is a biopharmaceutical company based in Seattle, Washington, focused on developing innovative protein therapeutic candidates for autoimmune and inflammatory diseases, as well as cancer. Its lead product candidate, AZ01, is currently in a Phase 1b clinical trial aimed at treating relapsing-remitting multiple sclerosis. The company is also advancing AZ17, a bispecific antibody designed for various autoimmune and inflammatory conditions, including Crohn's disease and multiple sclerosis, and AZ05, an antibody-drug conjugate targeting solid tumors. Founded in 2004, Allozyne is dedicated to enhancing the efficacy, safety, and dosing of protein-based therapeutics, including peptides and antibodies. It operates as a subsidiary of Poniard Pharmaceuticals, Inc.
Astria Therapeutics
Series B in 2013
Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.
G1 Therapeutics
Series A in 2013
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.
ADC Therapeutics
Series B in 2013
ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company is advancing its lead product candidates, including ADCT-402, which is undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, currently in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. In addition to these, ADC Therapeutics is developing other clinical-stage candidates like ADCT-601 and ADCT-602, as well as several preclinical candidates. The company utilizes advanced pyrrolobenzodiazepine (PBD) dimer technology, which enhances the potency and specificity of its ADCs compared to earlier generations. ADC Therapeutics has established a collaboration and licensing agreement with Genmab A/S to further its research and development efforts. The company was founded in 2011 and continues to focus on innovative cancer therapies.
Spirogen
Acquisition in 2013
Spirogen is a clinical-stage biotechnology company focused on the development of novel, sequence-selective DNA minor groove-binding molecules for cancer treatment. Founded in 2000, the company specializes in modifying naturally occurring antibiotics known as pyrrolobenzodiazepines (PBDs) to create therapeutic agents. Spirogen's key technologies include a C2 unsaturated pyrrolobenzodiazepine dimer and a hydrolysis-activated pyrrolobenzodiazepine dimer, as well as an achiral analog of duocarmycin. These compounds are designed to bind and cross-link specific sites of DNA in cancer cells without distorting the DNA helix, offering a targeted approach to therapy. With a workforce of 18 employees, Spirogen operates as a privately funded entity.
Inotek Pharmaceuticals
Venture Round in 2013
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.
Inotek Pharmaceuticals
Debt Financing in 2013
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.
Amplimmune
Acquisition in 2013
Amplimmune is focused on developing immune-based biologics aimed at treating patients with cancer, autoimmunity, transplantation issues, and infectious diseases. Founded by scientific experts from Johns Hopkins University, the company leverages key immunological ligands and receptors to create a new class of biological treatments. These treatments target immunological checkpoint and co-stimulatory molecules, which are crucial for modulating the body's immune system. By addressing critical mechanisms associated with aberrant immunological conditions, Amplimmune aims to improve the quality of life for affected patients.
AlphaCore Pharma
Acquisition in 2013
AlphaCore Pharma operates as a biopharmaceutical company.
Astria Therapeutics
Venture Round in 2013
Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.
AGTC
Series B in 2012
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.
Ambit Biosciences
Venture Round in 2012
Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.
Cerapedics
Series C in 2012
Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.
Coferon
Series B in 2012
Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.
Astria Therapeutics
Series A in 2011
Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.
Inotek Pharmaceuticals
Series D in 2011
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.
Ambit Biosciences
Series D in 2011
Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.
Astria Therapeutics
Series A in 2010
Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.
Corridor Pharmaceuticals
Series A in 2010
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Astria Therapeutics
Series A in 2010
Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.
VentiRx Pharmaceuticals
Series A in 2010
VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company based in Seattle, Washington, focused on developing and commercializing immunotherapies targeting Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Founded in 2006, the company’s lead investigational drug, Motolimod, works by mobilizing the patient's immune system to fight cancer through the activation of myeloid dendritic cells, monocytes, and natural killer cells. VentiRx's product pipeline includes VTX-2337, a TLR8 agonist aimed at enhancing immune responses against solid tumors and specific cancers such as ovarian and breast cancer, as well as VTX-1463, designed to address allergies. The company is also exploring TLR8 antagonists for autoimmune diseases and compounds intended as vaccine adjuvants. VentiRx Pharmaceuticals operates as a subsidiary of Celgene Corporation and has additional operations in San Diego.
Virdante Pharmaceuticals
Series A in 2009
Virdante Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the development and commercialization of drugs for autoimmune and inflammatory diseases. Founded in 2007 and previously known as Centaurus Pharmaceuticals, the company specializes in creating antibody and Fc-fusion therapies aimed at addressing various autoimmune conditions. Through its innovative research and development efforts, Virdante Pharmaceuticals seeks to improve treatment options for patients suffering from these disorders.
Corridor Pharmaceuticals
Series A in 2009
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Ligocyte Pharmaceuticals
Series C in 2009
LigoCyte Pharmaceuticals is focused on developing innovative treatments for inflammatory and infectious diseases through its research on immunomodulatory drugs and therapeutic monoclonal antibodies. The company specializes in creating vaccines and monoclonal antibodies for respiratory and gastrointestinal conditions, including commercial vaccines and biodefense products. Notable offerings include Norovirus VLP Vaccines, which mimic the virus's surface without causing infection, and an Influenza VLP Vaccine that protects against various strains of the virus, including A/H1N1 and A/H3N2. Additionally, LigoCyte is developing an anthrax vaccine and the Anti-CD103 Monoclonal Antibody, which aids in the retention of activated lymphocytes at sites of inflammation. With a focus on advancing its proprietary products into human clinical testing, LigoCyte aims to contribute significantly to the biotechnology sector and improve patient outcomes.
VaxInnate
Series D in 2009
VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.
AGTC
Venture Round in 2009
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.
NKT Therapeutics
Series A in 2009
NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing therapeutics that leverage natural killer T (NKT) cells. Established in 2008, the company aims to create a pipeline of innovative NKT-based therapies targeting various conditions, including cancer, sickle cell disease, autoimmune and inflammatory diseases, as well as asthma. NKT Therapeutics utilizes its expertise to develop humanized monoclonal antibodies that specifically target and deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. Through its research and development efforts, the company seeks to address significant medical needs and improve treatment outcomes for patients suffering from these challenging conditions.
Melinta Therapeutics
Series D in 2009
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.
Hydra Biosciences
Series D in 2009
Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.
Corridor Pharmaceuticals
Seed Round in 2008
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
BrainCells
Series B in 2008
BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.
Ambit Biosciences
Series D in 2007
Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.
Altiris Therapeutics
Series B in 2007
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer. The company offers CXCR4 receptor, which acts as a mediator of cellular and chemical trafficking; and Emtriva, which is used for the treatment of HIV Infection. Altiris Therapeutics was founded in 2005 and is based in Atlanta, Georgia.
Inotek Pharmaceuticals
Series C in 2007
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.
Sequoia Pharmaceuticals
Series C in 2007
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.
VaxInnate
Series C in 2006
VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.
Kemia
Series C in 2006
Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.
VLST Corporation
Series B in 2006
VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.
Avidia
Series C in 2006
Avidia, Inc. is a biopharmaceutical company based in Mountain View, California, that focuses on the discovery and development of therapeutic proteins. Founded in 2003, the company specializes in creating Avimer therapeutic proteins designed to treat a range of conditions, including autoimmunity, inflammation, oncology, and neurology. Avidia aims to innovate in the field of protein therapeutics to address significant medical needs across these therapeutic areas.
Inotek Pharmaceuticals
Series B in 2005
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.
Cellective Therapeutics
Acquisition in 2005
Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.
Avidia
Series B in 2005
Avidia, Inc. is a biopharmaceutical company based in Mountain View, California, that focuses on the discovery and development of therapeutic proteins. Founded in 2003, the company specializes in creating Avimer therapeutic proteins designed to treat a range of conditions, including autoimmunity, inflammation, oncology, and neurology. Avidia aims to innovate in the field of protein therapeutics to address significant medical needs across these therapeutic areas.
Receptor BioLogix
Series A in 2005
Receptor BioLogix is a biotechnology company based in Palo Alto, California, focused on developing receptor-based biological therapeutics for the treatment of cancer, inflammatory, and autoimmune diseases. The company has created Hermodulins, which are pan-HER ligand traps designed to inhibit feedback mechanisms that can reduce the effectiveness of various cancer therapies. These innovations have shown anti-cancer potential in preclinical studies. Additionally, Receptor BioLogix is advancing its Intron Fusion Protein platform, which aims to discover novel splice variants of human proteins that may possess therapeutic potential.
Cellective Therapeutics
Series A in 2004
Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.
Inotek Pharmaceuticals
Series A in 2004
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.
VaxInnate
Series B in 2004
VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.
AGTC
Venture Round in 2003
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.
Critical Therapeutics,Inc.
Series B in 2003
Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.
Tercica
Series B in 2003
Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.
Iomai
Series C in 2003
Iomai Corporation specializes in the discovery and development of vaccines and immune system stimulants using a unique, needle-free approach known as transcutaneous immunization (TCI). This technology utilizes antigen-presenting cells located in the outer layers of the skin to enhance immune responses, allowing for the improvement of existing vaccines and the creation of new ones that can only be administered through this method. Founded in 1997 and based in Gaithersburg, Maryland, Iomai aims to expand the global vaccine market. Following its acquisition by Intercell Ag, the company was rebranded as Intercell USA, Inc. and now operates as a subsidiary of Intercell Biomedical Research & Development AG.
Panacea Pharmaceuticals
Series B in 2002
The Company has collaborated with M.D. Anderson Cancer Center in Houston, Texas; Massachusetts Institute of Technology in Cambridge, Massachusetts; and Rhode Island Hospital/Brown University in Providence, Rhode Island where teams of researchers are continuing advances on the Company's core technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.